Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies

References

• FalkRHAtrial fibrillationN Engl J Med20013441067107811287978
   PubMed Web of Science ®Google Scholar
• WatsonTShantsilaELipGYHMechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisitedLancet200937315516619135613
   PubMed Web of Science ®Google Scholar
• RomeroJRMorrisJPikulaAStroke prevention: modifying risk factorsTher Adv Cardiovasc Dis2008228730319124428
   PubMedGoogle Scholar
• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA20012852370237511343485
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDMWangTJLeipEPLifetime risk for development of atrial fibrillation: the Framingham Heart StudyCirculation20041101042104615313941
   PubMed Web of Science ®Google Scholar
• FeinbergWMBlackshearJLLaupacisAKronmalRHartRGPrevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implicationsArch Intern Med19951554694737864703
   PubMed Web of Science ®Google Scholar
• RogerVLGoASLloyd-JonesDMHeart disease and stroke statistics – 2012 update: a report from the American Heart AssociationCirculation2012125e2e22022179539
   PubMed Web of Science ®Google Scholar
• HeidenreichPATrogdonJGKhavjouOAForecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationCirculation201112393394421262990
   PubMed Web of Science ®Google Scholar
• MahanCEHoldsworthMTWelchSMBorregoMSpyropoulosACDeep-vein thrombosis: a United States cost model for a preventable and costly adverse eventThromb Haemost201110640541521833446
   PubMed Web of Science ®Google Scholar
• WolfPAMitchellJBBakerCSKannelWBD’AgostinoRBImpact of atrial fibrillation on mortality, stroke, and medical costsArch Intern Med19981582292349472202
   PubMed Web of Science ®Google Scholar
• FangMCSingerDEChangYGender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) studyCirculation20051121687169116157766
   PubMed Web of Science ®Google Scholar
• FusterVRydénLECannomDSACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyCirculation2006114e257e35416908781
   PubMed Web of Science ®Google Scholar
• LipGYNieuwlaatRPistersRLaneDACrijnsHJRefining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillationChest201013726327219762550
   PubMed Web of Science ®Google Scholar
• WangTJMassaroJLevyDA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart StudyJAMA20032901049105612941677
   PubMed Web of Science ®Google Scholar
• LipGYImplications of the CHA(2)DS(2)-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillationAm J Med201112411111420887966
   PubMed Web of Science ®Google Scholar
• GageBFYanYMilliganPEClinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)Am Heart J200615171371916504638
   PubMed Web of Science ®Google Scholar
• HyersTMAgnelliGHullRDAntithrombotic therapy for venous thromboembolic diseaseChest2001119176S193S11157648
   PubMed Web of Science ®Google Scholar
• De CaterinaRThe current role of anticoagulants in cardiovascular medicineJ Cardiovasc Med200910595604
   Google Scholar
• HartRGPearceLAAguilarMIMeta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillationAnn Intern Med200714685786717577005
   PubMed Web of Science ®Google Scholar
• FlockhartDAO’KaneDWilliamsMSPharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarinGenet Med20081013915018281922
   PubMed Web of Science ®Google Scholar
• GageBFFihnSDWhiteRHManagement and dosing of warfarin therapyAm J Med200010948148811042238
   PubMed Web of Science ®Google Scholar
• BrassLMKrumholzHMScintoJMRadfordMWarfarin use among patients with atrial fibrillationStroke199728238223899412618
   PubMed Web of Science ®Google Scholar
• AlbersGWYimJMBelewKMStatus of antithrombotic therapy for patients with atrial fibrillation in university hospitalsArch Intern Med1996156231123168911237
   PubMedGoogle Scholar
• HylekEMGoASChangYHenaultLESelbyJVSingerDEEffect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillationN Engl J Med20033491019102612968085
   PubMed Web of Science ®Google Scholar
• HylekEMSkatesSJSheehanMASingerDEAn analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillationN Engl J Med19963355405468678931
   PubMed Web of Science ®Google Scholar
• DarkowTVanderplasAMLewKHKimJHauchOTreatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care systemCurr Med Res Opin2005211583159416238898
   PubMed Web of Science ®Google Scholar
• McCormickDGurwitzJHGoldbergRJPrevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care settingArch Intern Med20011612458246311700158
   PubMed Web of Science ®Google Scholar
• JonesMMcEwanPMorganCLPetersJRGoodfellowJCurrieCJEvaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British populationHeart20059147247715772203
   PubMed Web of Science ®Google Scholar
• AnsellJEWeitzJIComerotaAJAdvances in therapy and the management of antithrombotic drugs for venous thromboembolismHematology Am Soc Hematol Educ Program200026628411701546
   PubMedGoogle Scholar
• ChambersSChaddaSPlumbJMHow much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic reviewInt J Lab Hematol20103242744219930411
   PubMed Web of Science ®Google Scholar
• MantJHobbsFDFletcherKWarfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trialLancet200737049350317693178
   PubMed Web of Science ®Google Scholar
• WannLSCurtisABJanuaryCT2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20115722324221177058
   PubMed Web of Science ®Google Scholar
• GuyattGHAklEACrowtherMGuttermanDDSchuünemannHJExecutive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121417S47S22315257
   PubMed Web of Science ®Google Scholar
• ConnollySJPogueJHartRGEffect of clopidogrel added to aspirin in patients with atrial fibrillationN Engl J Med20093602066207819336502
   PubMed Web of Science ®Google Scholar
• CammAJKirchhofPLipGYfor the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Guidelines for the management of atrial fibrillationEur Heart J2010312369242920802247
   PubMed Web of Science ®Google Scholar
• Di NisioMMiddeldorpSBullerHRDirect thrombin inhibitorsN Engl J Med20053531028104016148288
   PubMed Web of Science ®Google Scholar
• Pradaxa^® (dabigatran etexilate) product informationRidgefield, CTBoehringer-Ingelheim Pharmaceuticals Inc2012
   Google Scholar
• Xarelto^® (rivaroxaban) product informationTitusville, NJJanssen Pharmaceuticals Inc2011
   Google Scholar
• HirshJBauerKADonatiMBParenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)Chest2008133Suppl 6141S159S18574264
   PubMed Web of Science ®Google Scholar
• AlbersGWDienerHCFrisonLXimelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trialJAMA200529369069815701910
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStähleHGansserDRothWThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBr J Clin Pharmacol20076429230317506785
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med20093611139115119717844
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSReillyPAWallentinLNewly identified events in the RE-LY trialN Engl J Med20103631875187621047252
   PubMed Web of Science ®Google Scholar
• HartRGDienerHCYangSIntracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran. The RE-LY TrialStroke2012431511151722492518
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety CommunicationUpdate on the risk for serious bleeding events with the anticoagulant Pradaxa Available from: http://www.fda.gov/Drugs/DrugSafety/ucm326580.htmAccessed November 26, 2012
   Google Scholar
• UchinoKHernandezAVDabigatran association with higher risk of acute coronary events. Meta-analysis of noninferiority randomized controlled trialsArch Intern Med201217239740222231617
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJfor the ROCKET-AF InvestigatorsRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med201136588389121830957
   PubMed Web of Science ®Google Scholar
• TurpieAGLassenMRDavidsonBLRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialLancet20093731673168019411100
   PubMed Web of Science ®Google Scholar
• KakkarAKBrennerBDahlOEExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialLancet2008372313918582928
   PubMed Web of Science ®Google Scholar
• EikelboomJWO’DonnellMYusufSRationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatmentAm Heart J201015934835320211294
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med201136598199221870978
   PubMed Web of Science ®Google Scholar
• SchulmanSCrowtherMAHow I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switchBlood20121193016302322302737
   PubMed Web of Science ®Google Scholar